Blocking CD47 on NK cells has been demonstrated to increase their antitumoral activity in a syngeneic melanoma model38, while blocking CD47 on leukemia cells or major histocompatibility complex (MHC)-I-deficient cells increased the killing capacity of NK cells.39 This evidence concerns the gene CD47 and leukemia.